AbSci Corporation (ABSI)

ABSI here we go blue sky break 11.00…the AI bio beast of 2026

Sold at 9.31 - this was never high on my hot list, 286% from $2.56 SO BYE BYE

Absci Shares Soar After Positive Early Clinical Results for Hair Loss Therapy (ABSI)June 24, 2026 8:59 AM
IH Market News Absci Corporation (NASDAQ:ABSI) shares surged 24% on Wednesday after the biotechnology company reported encouraging interim Phase 1 safety data for ABS-201, its experimental antibody treatment for hair loss. The results provided an early boost to investor confidence as the company advances the candidate through clinical development for androgenetic alopecia, the most common form of hair loss. Phase 1 Trial Meets Key Safety Objectives According to Absci, ABS-201 was generally well tolerated across all blinded single ascending dose cohorts evaluated in the ongoing study. The trial enrolled 32 healthy adult participants who received intravenous doses ranging from 150 mg to 1,800 mg across four separate cohorts. The company reported no serious adverse events during the study. Most treatment-emergent adverse events were classified as mild, with the only moderate event being a headache reported in the third cohort. Investigators determined that the event was unlikely to be related to the treatment. The favorable safety profile supports continued development of the therapy and progression into subsequent stages of testing. ABS-201 Targets Androgenetic Alopecia ABS-201 is an anti-prolactin receptor antibody being developed to treat androgenetic alopecia, a condition that affects an estimated 80 million people in the United States. The therapy is designed to target biological pathways associated with hair loss and could offer a differentiated treatment approach compared with currently available options. Pharmacokinetic data from the study indicated an estimated half-life of at least 65 days. According to the company, the long duration of activity could support a treatment schedule involving only two or three injections over a six-month period. Multiple-Dose Study Already Underway Following the positive initial safety findings, Absci has begun enrolling participants in the first multiple ascending dose cohort involving individuals diagnosed with androgenetic alopecia. The next stage of the study is expected to provide important insights into the drug’s efficacy and its ability to promote meaningful clinical improvements in hair growth. Management expects to release interim proof-of-concept results during the second half of 2026. Full proof-of-concept data are anticipated in early 2027. Company Raises $100 Million to Support Development Pipeline Alongside the clinical update, Absci announced the pricing of an underwritten public offering consisting of 13.5 million shares. The shares were priced at $7.41 each and are expected to generate gross proceeds of approximately $100 million before underwriting fees and related expenses. The financing attracted participation from several prominent healthcare and institutional investors, including Eli Lilly & Company, Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile and another large investment management firm. Funding to Advance Hair Loss and Endometriosis Programs Absci said the proceeds will be used to support the continued development of ABS-201 in both androgenetic alopecia and endometriosis. The company also plans to launch a Phase 2 clinical trial for endometriosis later this year. The successful financing strengthens Absci’s balance sheet and provides additional resources to advance multiple programs through key clinical milestones. Investors Focus on Upcoming Efficacy Data The strong market reaction reflects growing investor optimism following the positive safety results and the company’s ability to secure significant new capital. With proof-of-concept data expected over the next 12 months and additional clinical studies planned, investors are increasingly focused on whether ABS-201 can demonstrate meaningful efficacy in treating hair loss and support its potential as a future commercial product. The latest results mark an important step forward for the program as Absci continues building its clinical pipeline in areas of significant unmet medical need. Absci Corporation stock priceThe post Absci Shares Soar After Positive Early Clinical Results for Hair Loss Therapy (ABSI) appeared first on US Editors. Original: Absci Shares Soar After Positive Early Clinical Results for Hair Loss Therapy (ABSI)

Nice bounce on the offering.

Where are you clown

The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath ItJune 16, 2026 8:45 AM
PR Newswire (US) Issued on behalf of MindWalk Holdings Corp.Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.NEW YORK, June 16, 2026 /PRNewswire/ -- Equity Insider News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, models that can predict how a protein folds or design an antibody from scratch. But a quieter and increasingly influential argument is taking hold among the people actually building these systems: in biology, the model may be the least durable part of the equation. Models improve, get copied, and get commoditized. What is hard — and potentially far more valuable — is the connected, trustworthy biological knowledge the model has to reason over in the first place. Feed even a brilliant model fragmented, contradictory data and it will, in the words of one industry executive, confidently get it wrong. That debate moves to center stage on June 15, 2026, when MindWalk Holdings Corp. (NASDAQ: HYFT) joins a virtual investor panel hosted by research firm Jones — alongside generative-biology company Absci (NASDAQ: ABSI) and a leading AI compute provider — titled "Partnering to Power the New Era of Drug Discovery." The panel is a small event, but it sits on top of one of the most consequential questions in biotech: as the industry pours capital into AI, what is the part that actually compounds in value? MindWalk's answer — and the trajectory of the broader field — is worth understanding now, because it reframes where the durable advantages in AI-driven medicine may ultimately lie.Why AI Drug Discovery Hit a Wall — and What ChangedThe promise of applying AI to drug discovery has always been intoxicating: compress the decade-plus, billion-dollar odyssey of finding and validating a new medicine into something faster, cheaper, and more likely to succeed. The early wave of "AI-first" biotechs raised enormous sums on that promise. But the field ran into a hard truth that has little to do with algorithms. Biological data is a mess. It is scattered across incompatible files, formats, instruments, lab notebooks, and decades of literature; it is riddled with gaps and contradictions; and the relationships that matter most — how a sequence maps to a structure, a function, a mechanism, a disease — are often implicit rather than recorded. A model trained or prompted on that fragmented foundation can produce fluent, confident answers that are simply wrong, a failure mode the field has come to call hallucination.In consumer applications, a hallucinating chatbot is an annoyance. In drug discovery, it is a multimillion-dollar wrong turn, sending scientists down a path toward a target or molecule that was never viable. As the industry now races to deploy not just static AI models but autonomous "agentic" systems — AI that can plan and execute multi-step research workflows with limited human supervision — the cost of bad underlying data multiplies. An agent acting on fragmented biology does not just give one wrong answer; it compounds the error across an entire chain of decisions. That escalating risk is exactly why attention is shifting from the models themselves to the integrity of the biological foundation they operate on.MindWalk's Bet: Own the Context Layer, Not the ModelMindWalk — a company that rebranded in 2025 from its prior identity as ImmunoPrecise Antibodies, unifying its operations and adopting the Nasdaq ticker HYFT — has built its entire strategy around that shift. Rather than competing to build the flashiest model, the company positions its durable asset as the layer underneath: a biological "context layer" that connects and enriches data before any model reasons over it. Its proprietary HYFT® Technology, refined over roughly two decades of curation, is described as a continuously evolving biological representation spanning 660 million biological patterns and 25 billion relationships — a kind of connective tissue that links sequences, structures, functions, mechanisms, pathways, evidence, and literature into a single queryable foundation.On top of that foundation sit two products the company has brought to market. ReefIQ™, launched in June 2026, is pitched as the biological context layer that sits between a client's fragmented discovery data and its AI reasoning workflows — reconnecting the pieces before the AI acts. LensAI™ is the reasoning and application layer used for target discovery, candidate diligence, and portfolio decision support, and increasingly to host the agentic workflows pharma is racing to adopt. The company's central thesis, which CEO Dr. Jennifer Bath is expected to articulate on the Jones panel, is that because its predictions are grounded in what evolution has already conserved — the functional patterns that have survived across biology — rather than in raw statistical correlation, the system is designed to keep both models and agents from hallucinating in the highest-consequence workflows. Bath has framed the convergence she sees as "biology, context, and compute."Importantly, this is not purely conceptual. MindWalk reported that its largest enterprise AI client signed a one-year LensAI platform contract — the first contracted, recurring platform-revenue agreement in the company's history — and that the structure is one it intends to scale across its client base. For its fiscal third quarter ended January 31, 2026, the company reported revenue of $4.2 million (in Canadian dollars), up 52% year-over-year and a third consecutive quarter of year-over-year growth, with U.S. revenue doubling. The company also reported preclinical dengue data that, by its account, supported a computational prediction its platform generated before any animal was immunized — an early, real-world validation of the approach.The Field Around MindWalkMindWalk is one expression of a sector that has matured well beyond the first hype cycle, and looking at how a few public peers are positioned helps frame both the opportunity and where MindWalk's niche sits within it. Each of these companies attacks the AI-drug-discovery problem from a different layer of the stack.Absci Corporation (NASDAQ: ABSI) — MindWalk's fellow panelist — represents the generative-design frontier. The company uses generative AI models paired with an integrated wet lab to design therapeutic antibodies essentially from scratch, conditioning its models on a target's structure and then validating proposals through high-throughput experiments. Absci became clinical-stage with an AI-designed antibody entering a Phase 1 trial, making it a closely watched proof point for whether generative design can produce real drugs. It illustrates the "design" layer of the field — complementary to the data-foundation layer MindWalk emphasizes.Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is among the largest and best-known "AI-first" drug discovery platforms, having industrialized the generation of biological data through massive automated experimentation and paired it with machine learning to identify drug candidates. With collaborations involving major pharmaceutical companies and its own clinical-stage pipeline, Recursion represents the scaled, full-stack ambition of the sector — building both the data engine and the drug pipeline — and the patient capital that strategy requires.Schrödinger, Inc. (NASDAQ: SDGR) approaches the problem from a different intellectual tradition: physics-based computational chemistry. Its software platform simulates how molecules behave at a fundamental level to predict which candidates are worth pursuing, and it both licenses that software to the industry and advances its own pipeline. Schrödinger illustrates the established, software-led end of the field — a reminder that "computational drug discovery" predates the current AI wave and that different modeling philosophies coexist and compete.Certara, Inc. (NASDAQ: CERT) rounds out the group as the infrastructure-and-decision-support comparison closest in spirit to MindWalk's positioning. A leader in biosimulation and model-informed drug development, Certara provides software and AI-powered services used across the drug-development lifecycle, including in regulatory submissions. As one of the more established, revenue-generating names in the space, it demonstrates that there is a durable, infrastructure-layer business in AI-enabled drug development — the same category MindWalk is targeting with its context layer, albeit at a far larger and more mature scale. These companies are referenced to illustrate the sector and do not imply any partnership, endorsement, affiliation, or comparable financial performance; they differ widely in approach, size, and stage, and MindWalk is among the smaller, earlier-stage names. References to Absci, Jones, and the other panelists describe the event only and do not imply any endorsement or commercial relationship.The Investment Case — and the RisksThe bull case for the context-layer thesis is conceptually elegant. If models are destined to commoditize — and the pace at which capable AI models now proliferate suggests they might — then the enduring value in AI drug discovery accrues to whoever owns the trusted, connected biological foundation that every model and agent must rely on. A context layer, in that telling, becomes infrastructure: something pharma rents rather than rebuilds, with recurring revenue and compounding value as more data and more programs run through it. MindWalk's first recurring platform contract and its growing revenue are early evidence that customers may be willing to pay for exactly that.The risks, however, are substantial and should not be minimized. MindWalk is a small-cap company still posting operating losses as it transitions from a legacy wet-lab services business toward a scalable platform model. Its revenue, while growing, is modest in absolute terms, and the company depends on converting engagement into contracted, recurring arrangements that have only just begun. It relies on third-party compute and cloud providers, faces intense competition from larger and better-funded players, and operates in a field where adoption of bio-native and agentic AI could prove slower than hoped. As with any clinical- or platform-stage life-sciences company, there is no certainty that the capabilities described will translate into commercial success, and forward-looking claims about the technology remain just that — forward-looking.A Sector Finding Its Real FoundationWhat makes this moment interesting is not any single company or any single panel. It is that the AI-drug-discovery field appears to be maturing past its first, model-obsessed phase into a more sophisticated understanding of where value actually lives. The lesson emerging from the first wave — that pointing powerful AI at messy biology produces confident nonsense — has pushed serious players toward the unglamorous but essential work of connecting and grounding biological knowledge. Whether the durable advantage ultimately sits in generative design, industrialized data generation, physics-based simulation, or a connected context layer is precisely the question a panel like the one on June 15 exists to debate.MindWalk has placed a clear, focused bet on the context layer — that in the age of agentic AI, the biology has to be connected and trustworthy before a model ever acts on it, and that owning that foundation is the durable prize. It is an early-stage bet, with real execution and financing risk, and the market has yet to render its verdict. But the trajectory of the field is unmistakable: the conversation has moved from "whose model is biggest" toward "whose biology is most trustworthy," and the companies building that foundation are positioning themselves at what may prove to be the most defensible layer of the entire AI-medicine stack. For investors trying to understand where the next decade of drug discovery is headed, that shift is the story worth watching.SEE WHAT THE MARKET IS TALKING ABOUT BEFORE IT MOVESEagle Eye reads social, forum, and news chatter across thousands of investor conversations in real time — and surfaces the tickers the crowd is piling into, along with the sentiment and catalysts behind them.Explore Eagle Eye free (for now) at https://Eagle-Eye.devCONTACT:Equity Insiderinfo @therooster-2873SOURCES:[1] MindWalk Holdings Corp. — "MindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel…" (Business Wire, June 12, 2026; primary source for the panel, HYFT/ReefIQ/LensAI platform, Bath quote, 660M patterns / 25B relationships):
https://finance.yahoo.com/sectors/healthcare/articles/mindwalk-nasdaq-hyft-ceo-dr-130000157.html[2] MindWalk Holdings Corp. — "Launches ReefIQ™, a Biological Context Layer for AI Drug Discovery" (Business Wire, June 10, 2026; ReefIQ context-layer detail):
https://www.businesswire.com/news/home/20260610294167/en/MindWalk-Holdings-Corp.-NASDAQ-HYFT-Launches-ReefIQ-a-Biological-Context-Layer-for-AI-Drug-Discovery[3] MindWalk Holdings Corp. — "Reports Q3 Fiscal 2026 Financial Results" (Business Wire, March 12, 2026; $4.2M revenue +52% YoY, first recurring LensAI contract, subsidiaries):
https://www.businesswire.com/news/home/20260312858299/en/MindWalk-Holdings-Corp.-Reports-Q3-Fiscal-2026-Financial-Results[4] MindWalk Holdings Corp. — "ImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to 'HYFT'" (Business Wire, Sept 3, 2025; rebrand, platform business-model shift):
https://www.businesswire.com/news/home/20250903938726/en/ImmunoPrecise-Rebrands-as-MindWalk-Announces-NASDAQ-Ticker-Change-to-HYFT[5] BioPharmaTrend — "Publicly Traded AI-driven Drug Discovery Companies" and related sector coverage (peer context: Absci, Recursion, Schrödinger, Certara):
https://www.biopharmatrend.com/artificial-intelligence/recent-ipos-among-ai-driven-platforms-for-drug-discovery-and-biotech-601/DISCLAIMER:Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a digital media distribution and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances.Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). This article is being distributed by Equity Insider on behalf of MIQ. MIQ has been paid a fee for MindWalk Holdings Corp. advertising and digital media from Creative Direct Marketing Group ("CDMG"). This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this article or email as the basis for any investment decision. MIQ does not own shares of MindWalk Holdings Corp. but reserves the right to buy and sell shares of MindWalk Holdings Corp. at any time without any further notice. There may be 3rd parties who may have shares of MindWalk Holdings Corp., and may liquidate their shares which could have a negative effect on the price of the stock. We also expect further compensation as an ongoing digital media effort to increase visibility for the company; no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been reviewed and approved on behalf of MindWalk Holdings Corp. by CDMG; this is a digital media distribution.While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our publication is not trustworthy unless verified by their own independent research. Comparisons to other companies referenced in this publication are for contextual and illustrative purposes only and do not imply any partnership, endorsement, affiliation, or comparable financial performance. References to the Jones AI Day panel, Absci, and other panelists describe the event only and do not imply any endorsement, sponsorship, partnership, or commercial relationship. Forward-looking statements regarding technology, platform adoption, recurring revenue, clinical and preclinical outcomes, and market trends are subject to risks and uncertainties, and actual results may differ materially. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. View original content to download multimedia:https://www.prnewswire.com/news-releases/the-quiet-bottleneck-in-ai-drug-discovery-isnt-the-model--its-the-biology-underneath-it-302800965.html Original: The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It

Hello All:
Please take the time to review Helloman1's last 50 or 100 posts.
1. every post is mean spirited and full of hate
2. no posts are positive or encouraging.
we may conclude that this person is bitter and very unhappy in life.
throwing negativity and spewing harsh words is a sign of bigger things going on in (his) life.
3. Let's keep this in mind, ignore all of his posts, and feel sorry for this (pre dementia/ bi-polar/ shitzophrenic) loser.

Thank you for your attention to this matter.👍️

Stay away from this garbage.

ABSI THE BIO BEAST A BEASTVILLE...WEEKLY SMASH AND GRAB BREAK OUT

Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 4, 2026

Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced that on May 1, 2026, the company granted a non-statutory stock option to purchase an aggregate of 276,200 shares of its common stock to one newly-hired non-executive employee. The inducement grant was previously approved by the Compensation Committee of Absci’s Board of Directors pursuant to Absci’s 2023 Inducement Plan (the “Inducement Plan”), and is being made as an inducement material to the new employee’s acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock option award has an exercise price of $4.92 per share, the closing price of Absci’s common stock on the Nasdaq Global Select Market on May 1, 2026 the (“Grant Date”). The stock option has a 10-year term and vests over four years, and 25% of the shares subject to the option vest and become exercisable on the one-year anniversary of the Grant Date and the remaining 75% of the shares subject to the option vest and become exercisable in 36 approximately equal monthly installments thereafter such that the shares underlying the option granted to the new employee will be fully vested on the fourth anniversary of the Grant Date, subject to the new employee’s continued service with Absci on each such date (subject to the terms and conditions of the Inducement Plan and the option award agreement covering the grant).

About Absci
Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci’s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics including ABS-201™, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern hair-loss. ABS-201 is also being investigated as a potential “best-in-class” therapeutic for endometriosis, a condition with significant unmet medical need and market potential. Absci is headquartered in Vancouver, WA, with AI Research Labs in New York City and Serbia, and an Innovation Center in Switzerland. Learn more at www.absci.com or follow us on LinkedIn (@absci), X (@Abscibio) and YouTube.

Absci® standard character mark, ABS-201™, and Integrated Drug Creation™ are trademarks and registered trademarks of Absci Corporation.

Investor Contact
Alexander D.H. Khan
Corporate Vice President
Head of Investor Relations
investors@absci.com

Media Contact
press@absci.com

Link article

$ABSI 🗞️

ABSI the bio beast that nobody is talking about

BIO BEAST BEASTING THROUGH BEASTVILLE

ABSI time for this bio to shine once again

I saw good news in report. 201 advancing. Good spot to.be in

40 million share short 18 days to cover last month it was 11 there's only about 40 million available shares to trade 80% close to of the 150 million are held by institutions which I'm sure some are leveraged short. Technically we're a 100% shorted. I'm holding 32,000 shares and I'm not selling until I hit six

Short interest. Ridiculous 25% of shares.
Have some good news please!

Someone tell GameStop boys. Lol

ABSI. Beautiful close to exit.

ABSI. Beautiful close. One more push!

ABSI. Bios hot breaking on weekly

ABSI. Bios hot breaking on weekly

ABSI. Bios hot breaking on weekly

$ABSI: With Oracle related news this Morning.... now $2.50

Remember....... today is 9/11


LIFE IS FLEETING.

Now........ hug your loved ones.... be kind............ AND MAKE SOME MEGA MONEY !!!!!!!!!


GO $ABSI

Short squeeze??? Looks good for one

Share Structure & Short Metrics
Outstanding shares: ~127.6?M

Float (public shares available): ~111.5?M StockAnalysis+11MarketBeat+11Seeking Alpha+11

Short interest: ~32.1?M shares, which is 28.8% of float (or ~25% of total shares) MarketBeat+1MarketBeat+1

Days to cover: ~9–10?days (varies by source: ~9.9 from MarketBeat, ~8.7 from StockAnalysis, ~6.7 from Fintel/Benzinga) Fintel+3MarketBeat+3Benzinga+3

Short interest trend: A ~23% increase in short interest in June, from ~26?M to ~32?M shares StockAnalysis+2MarketBeat+2Reddit+2

🔍 What This Means for a Possible Short Squeeze
A short squeeze is more likely when:

High short interest as percentage of float (=20%)

Elevated days to cover ratio (=5 days)

Catalysts like positive news or spikes in buying volume

ABSI checks the first two boxes:

Nearly 29% short float—substantially high

8–10 days to cover, indicating shorts would take a long time to unwind

Add in several bullish signals:

AI/ML-driven drug discovery partnerships (e.g., with AMD, Merck, AstraZeneca) Fintel+2Wikipedia+2Reddit+2MarketBeatBenzinga+3MarketBeat+3Fintel+3Wikipedia+5Reddit+5MarketBeat+5Yahoo Finance+10Reddit+10MarketBeat+10

Recent analyst upgrades (Needham, HC Wainwright, Guggenheim) with $7–$10 price targets MarketBeat

If ABSI experiences a strong positive catalyst or sharp price uptrend, the short sellers could be forced to scramble, buying to cover—a textbook setup for a short squeeze.

⚠️ Considerations & Risks
Volatile stock (high beta ~2.0–2.5)—price moves can be exaggerated Reddit+13Fintel+13Newser+13

A squeeze isn't guaranteed—market momentum and broader investor sentiment heavily influence outcomes

Catalyst-dependent—without a strong spark (earnings beat, major partnership, or takeover buzz), the squeeze may not materialize

✅ Bottom Line
ABSI has the classic technical setup for a short squeeze: very high short float, lengthy days to cover, and ongoing bullish interest. If positive news or a surge in buying pressure emerges, a squeeze could follow. But absent that catalyst, the stock may just meander or pull back, even though it's primed structurally.

Black Rock has been ringing the bell. Increase from five percent to over 6%, this quarter . I wonder what they know.

Patience is key with this one

It hasn't woken up yet, but the alarm is ringing. It only takes time..

ABSI MONSTER

GAPPED UP AH...BEAST!

Can it go to $60 next week like TEM or HIMS?

ABSI READY FOR 6.00

ABSI TRENDTRADE WEEKLY BREAK OUT

ABSI NEXT AI CANCER PLAY...MONSTER IN THE MAKING

ABSI: Clueless about it, since back then!! (THANKS for heads-up!!)

ABSI nice day $4s

Wow, President Trump just opened the flood gates for investments into AI and medical approaches. 7.55 before end of February.

Wow, President Trump just opened the flood gates for investments into AI and medical approaches. 7.55 before end of February.

https://www.technologynetworks.com/drug-discovery/articles/how-is-ai-being-used-in-drug-discovery-394789

Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery
07:30:00 AM ET, 01/10/2025 - GlobeNewswire

VANCOUVER, Wash. and PARIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to unlock complex targets for drug discovery, development, and diagnostics, today announced a partnership bringing together two leading AI platforms to rapidly discover and design novel therapeutics for patients.

“At Absci, we’re constantly pushing the boundaries of innovation to bring better biologics to patients faster,” said Sean McClain, Founder and CEO of Absci. “By combining Absci’s AI de novo design expertise with Owkin’s world-class predictive AI target discovery technology, we have a unique opportunity to design first-in-class and potentially transformative therapeutics for patients in need.”

Through this strategic partnership, Absci and Owkin will co-develop therapeutic candidates addressing novel targets in immuno-oncology and other indications, such as immunology and inflammation. Owkin’s predictive AI models will optimize target selection and validate therapeutic hypotheses using extensive biomedical datasets and patient-derived organoids. Absci’s generative AI Drug Creation platform, including its de novo antibody design models, will rapidly design therapeutic candidates against these novel targets. Together, the companies will aim to streamline and accelerate the path from research to clinical development.

“At Owkin, our mission is to use patient data and Owkin K, our Operating System, to revolutionize drug discovery and development,” said Thomas Clozel, MD, CEO and Co-Founder of Owkin. “This partnership with Absci represents a significant step forward in our journey to bring transformative therapies to patients. By bringing together Owkin’s AI agents that can identify and experimentally validate novel therapeutic targets with Absci’s pioneering capabilities in developing biologic drug candidates, we aim to accelerate the delivery of next-generation treatments.”

This collaboration builds on Absci’s growing portfolio of partnerships with industry leaders such as AstraZeneca and Merck, as well as its robust internal pipeline of drug candidates. With this new partnership, Absci has added drug creation partnerships with four new Partners in 2024, achieving the Company's outlook for the year. Similarly, Owkin has established itself as a pioneer in predictive AI, working with top-tier pharmaceutical companies such as Sanofi and BMS to advance drug discovery and development as well as its differentiated pipeline of drug candidates and AI diagnostics

ProMIS Neurosciences (PMN) announced the initiation of its Phase 1b clinical trial evaluating its lead therapeutic candidate, PMN310, in Alzheimer's disease.Absci Corporation (ABSI) announced a partnership bringing together two leading AI platforms to rapidly discover and design novel therapeutics for patients.Tourmaline Bio (TRML) announced that Paul M. Ridker, MD, MPH, Eugene Braunwald Professor of Medicine at the Harvard Medical School and Director of the Center for Cardiovascular Disease Prevention at Brigham and Women's Hospital, has joined Tourmaline's Cardiovascular Scientific Advisory Board.

AMD is investing $20 million in AI drug startup Absci , which will use AMD chips and software

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Absci (NASDAQ:ABSI) with a Buy and maintains $7 price target.

ABSI: I'm in --- nice deal with AMD!!

3rd quarter results Nov. 12, fyi ANT

2025 gettin' closer, ANT

Approachin' the end of the 6 month tradin' channel, gets interestin' now, fyi imvho ANT

C
A prescription drug bottle filled with 0s and 1s to represent binary code.Francis Scialabba
CFOs are embracing AI, experimenting with new use cases for it throughout the finance function. But some CFOs are tapping the potential of the technology in other ways. At biotech firm Absci, researchers are using AI to develop drugs to treat cancer. (We’re not saying that to make your Claude-drafted emails look bad, we promise.)

Absci’s CFO and CBO, Zach Jonasson, spoke with CFO Brew about how AI is allowing the company to create and test new antibodies faster—and cheaper—than ever before.

Absci uses E. coli—yes, the same bacteria that can give you some nasty infections—to manufacture antibodies that can be used in a variety of therapies. Using a process called “high throughput screening,” it then tests the antibodies, and it patents therapies containing the most promising ones.

Even before ChatGPT burst onto the scene, Absci saw potential in AI. Through its testing of antibodies, the company generated large amounts of data, which it realized could be used to train an AI. In 2021, it acquired a deep learning company called Denovium, which became “the nucleus” that it built a proprietary AI around, Jonasson said.

ABSI under $5

ABSI three month chart